Health
AHA: A Novel Monoclonal Antibody Therapy Cuts LDL Cholesterol by Half in a High-Risk Patient Population, Study Shows – Cath Lab Digest
November 16, 2020 — The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called “bad” cholesterol—by 50 percent in patients…
November 16, 2020 The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterolthe so-called bad cholesterolby 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, were presented as late breaking science at the American Heart Association Scientific Sessions 2020 on…
Continue Reading
